Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.79 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982788 | 1.00 | ADORA2A (0.79) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7459867 | 0.98 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7088617 | 0.95 | ADORA2A (0.79) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1978551 | 0.90 | ADORA2A (0.91) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1982789 | 0.90 | ADORA2A (0.91) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1978555 | 0.90 | ADORA2A (0.91) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1982786 | 0.90 | ADORA2A (0.91) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7609377 | 0.89 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL12273278 | 0.89 | ADORA2A (0.90) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7651022 | 0.89 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509606-A1 | NOVEL MEDICAL USE | Glaxo Group Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120238520-A1 | Novel Medical Use | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011069918-A1 | NOVEL MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238520-A1 | Novel Medical Use | FPR3, PTGES3, FPR2 | ADORA2A 87/4885ADORA3 63/4885ADORA1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.